Opening book details…
About this Medicine article
Corrigendum to “Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG oncology study (NRG-GY008)” [Gynecol. Oncol. Rep. 31 (2020) 100532] by Santin, Alessandro D.; Filiaci, Virginia; Bellone, Stefania; O'Cearbhaill, Roisin; Ratner, Elena S.; Mathews, Cara A.; Cantuaria, Guilherme; Gunderson, Camille C.; Rutledge, Teresa; Buttin, Barbara M.; Lankes, Heather A.; Birrer, Michael J. is a Medicine article available to read on EtoBox.
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- Santin, Alessandro D.; Filiaci, Virginia; Bellone, Stefania; O'Cearbhaill, Roisin; Ratner, Elena S.; Mathews, Cara A.; Cantuaria, Guilherme; Gunderson, Camille C.; Rutledge, Teresa; Buttin, Barbara M.; Lankes, Heather A.; Birrer, Michael J.
- Publisher
- Elsevier ; Elsevier BV; [Amsterdam]: Elsevier (ISSN 2352-5789)
- Published
- 2020
- Field
- Medicine (Health Sciences)